NEW YORK (GenomeWeb News) – Empire Genomics today announced it has received a Phase I SBIR grant from the National Cancer Institute to develop a genomic companion diagnostic test for multiple myeloma.

It is the first SBIR grant for Buffalo, NY-based Empire. The firm plans to use the funds to further develop its licensed technology for use in predicting multiple myeloma patient response to therapeutic treatments.

The grant lasts through October. According to the National Institutes of Health's grants database, the grant is for $142,432.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.